Author's response to reviews

Title: A 3D-microtissue-based phenotypic high content screen of chemotherapeutic drugs that overcome tumour resistance to radiation therapy

Authors:

Natasa Anastasov (natasa.anastasov@helmholtz-muenchen.de)
Ines Höfig (ines.hoefig@helmholtz-muenchen.de)
Vanja Radulovic (vanja.radulovic@helmholtz-muenchen.de)
Simon Ströbel (simon.stroebel@insphero.com)
Michael Salomon (Salomon@sirion-biotech.de)
Jan Lichtenberg (jan.lichtenberg@insphero.com)
Ina Rothenaigner (ina.rothenaigner@helmholtz-muenchen.de)
Kamyar Hadian (kamyar.hadian@helmholtz-muenchen.de)
Jens M Kelm (jens.kelm@insphero.com)
Christian Thirion (thirion@sirion-biotech.de)
Michael J Atkinson (atkinson@helmholtz-muenchen.de)

Version: 4 Date: 8 January 2015

Author's response to reviews: see over
Dear Ms. Cherry Battad,

In accord with revision request of **BMC Cancer Journal** herewith I submits the revised manuscript entitled:

‘A 3D-microtissue-based phenotypic high content screen of chemotherapeutic drugs that overcome tumour resistance to radiation therapy’ by Anastasov et al., for your further consideration.

**Response to EDITORIAL REQUESTS:**

1). **Please provide Line numbering.**

Line and page numbers are included. The line numbering is included in the main text file of the manuscript to facilitate peer-review. Title Page, Abstract and References are not included within the line numbering.

2). **Requesting Ethics statement.**

Statement about research involving human subjects (including human material or human data) has been included in Methods section (page 6, line 57 and 58). Only commercially available human cell lines were used in this study and therefore ethical approval is covered by material transfer agreement of using such human material for research purposes.

I hope revised manuscript will fulfil the issues for further peer-review process.

Sincerely,

Dr. Nataša Anastasov  
*Group Leader (Personalized Radiation Therapy)*

Institute of Radiation Biology  
Ingolstaedter Landstr. 1  
D-85764 Neuherberg  

Helmholtz Zentrum München  
P.O. Box 11 29  
85758 Neuherberg  

12.12.2014